Evaluation of lipid profile in patients with inflammatory bowel disease
DOI:
https://doi.org/10.15448/1980-6108.2016.2.22964Keywords:
doença de Crohn, retocolite ulcerativa, dislipidemias.Abstract
Aims: To evaluate the lipid profile and inflammatory parameters in patients with bowel disease, Crohn’s disease (CD), and ulcerative colitis (UC) and correlate them with disease activity levels.
Methods: Cross-sectional study of patients followed up at the Inflammatory Bowel Disease Outpatient Clinic of São Lucas Hospital at Pontifícia Universidade Católica do Rio Grande do Sul, Brazil. The demographic, anthropometric, and metabolic characteristics of patients with chronic inflammatory disease were evaluated. Lipids and inflammatory parameters were evaluated as well as the correlation between the severity of inflammatory disease and metabolic parameters using the Harvey-Bradshaw index for CD and Truelove and Witts’ method for UC.
Results: The study included 122 male and female patients with inflammatory bowel disease classified into CD (n=64) and UC (n=58). Women accounted for 54.1% of the sample, with a mean age of 41.6±12.6 years and a BMI of 25±4.4kg/m2. Low-density lipoprotein cholesterol (LDL-c) was significantly higher in UC than in CD (p=0.006). Higher C-reactive protein levels were associated with a more severe inflammatory process in CD patients (p=0.027) according to the Harvey-Bradshaw index. In UC, there was a weak correlation between disease activity and high-density lipoprotein cholesterol (HDL-c) (rs= -0.29; p=0.036) and between disease activity and total cholesterol (rs= -0.30; p=0.028) according to Truelove and Witts’ index. The HDL-c of about two thirds of the patients (67.6%) was below the recommended values.
Conclusions: LDL-c was significantly higher in patients with UC than in those with CD. HDL-c was lower in patients with more severe inflammatory disease triggered by UC. Increased C-reactive protein levels in CD patients were associated with severity of the inflammatory process determined by the Harvey-Bradshaw index. The detection of these metabolic changes may help identify individuals with potential risk for cardiovascular events.
Downloads
References
Brazilian Study Group of Inflammatory Bowel Diseases. Consensus guidelines for the management of inflammatory bowel disease. Arq Gastroenterol. 2010 Jul-Sep;47(3):313-25. http://dx.doi.org/10.1590/S0004-28032010000300019
Freeman HJ. Natural history and long-term clinical course of Crohn`s disease. World J Gastroenterol. 2014 Jan 7;20(1):31-6. http://dx.doi.org/10.3748/wjg.v20.i1.31
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn`s disease: definitions and diagnosis. J Crohns Colitis. 2010 Feb;4(1):7-27. http://dx.doi.org/10.1016/j.crohns.2009.12.003
World Gastroenterology Organisation Practice Guidelines. Doença inflamatória intestinal: uma perspectiva global. Milwaukee, WI: WGO; 2009.
Magro F, Cravo M, Lago P, Ministro P, Peixe P, Portela F, Ramos J,Tavares L. Portuguese consensus on the best practice for the management of inflmmatory bowel disease:IBD ahead 2010 meeting results. GE J Port Gastrenterol. 2012 Jul;19190-8.
Harvey R, Bradshaw J. A simpleindex of Crohn's Disease. Lancet. 1980 Mar 8;1(8167):514. http://dx.doi.org/10.1016/S0140-6736(80)92767-1
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. J Crohns Colitis. 2012 Dec;6(10):965-90. http://dx.doi.org/10.1016/j.crohns.2012.09.003
Hanauer SB, Rubin DT, Sandborn WJ. Treatment guidelines and clinical practice: optimizing foundational therapies for ulcerative colitis. Gastroenterol Hepatol. 2008 Oct;4(10 Suppl 22):1-16.
Sociedade Brasileira de Cardiologia. V Diretriz brasileira sobre dislipidemias e prevenção da aterosclerose. Arq Bras Cardiol. 2013;101(4 Supl 1):1-22. http://dx.doi.org/10.5935/abc.2013S010
Gandhi S, Narula N, Marshall JK, Farkouh M. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? Am J Med. 2012 Oct;125(10):956-62. http://dx.doi.org/10.1016/j.amjmed.2012.03.015
Williams HR, Willsmore JD, Cox IJ, Walker DG, Cobbold JF, Taylor-Robinson SD, Orchard TR. Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci. 2012 Aug;57(8):2157-65. http://dx.doi.org/10.1007/s10620-012-2127-2
Andersen NN, Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):359-65.
Cardozo WS, Sobrado CW. Doença inflamatória intestinal. 2a ed. Barueri, SP: Editora Manole; 2015.
Elia PP, Fogaça HS, Barros RGGR, Zaltman C, Elia CSC. Análise descritiva dos perfis social,clínico,laboratorial e antropométrico de pacientes com doenças inflamatórias intestinais, internados no Hospital Universitários Clementino Fraga Filho, Rio de Janeiro. Arq Gastroenterol. 2007;44(4):332-9. http://dx.doi.org/10.1590/S0004-28032007000400010
Victoria CR, Sassaki LY, Nunes HRC. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo state, Brazil. Arq Gastroenterol. 2009;46(1):20-4. http://dx.doi.org/10.1590/S0004-28032009000100009
Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009 Mar;21(3):283-8. http://dx.doi.org/10.1097/MEG.0b013e328325d42b
Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011;24(3):181-7.
Romanato G1, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, Zambon S, Basato S, Zanoni S, Filosa T, Pilon F, Manzato E. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther. 2009 Feb 1;29(3):298-307.
Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the cronh`s disease activity and harvey-bradshaw indices is assessing crohn`s disease severity. Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63. http://dx.doi.org/10.1016/j.cgh.2010.01.001
Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol. 2008 Jan 7;14(1):85-9. http://dx.doi.org/10.3748/wjg.14.85
Hrabovský V1, Zadák Z, Bláha V, Hyspler R, Karlík T, Martínek A, Mendlová A. Cholesterol metabolism in active Crohn's disease. Wien Klin Wochenschr. 2009;121(7-8):270-5. http://dx.doi.org/10.1007/s00508-009-1150-6
Souza MM, Belasco AGS, Aguilar-Nascimento JE. Perfil epidemiológico dos pacientes portadores de doença inflamatória intestinal do estado de Mato Grosso. Rev Bras Coloproct. 2008;28(3):324-8. http://dx.doi.org/10.1590/S0101-98802008000300009
Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010 Nov-Dec;4(6):478-82. http://dx.doi.org/10.1016/j.jacl.2010.08.021
Theocharidou E, Tellis CC, Mavroudi M, Soufleris K, Gossios TD, Giouleme O, Athyros VG, Tselepis AD, Karagiannis A. Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. J Crohns Colitis. 2014 Sep;8(9):936-44. http://dx.doi.org/10.1016/j.crohns.2014.01.016
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The submission of originals to Scientia Medica implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Scientia Medica as the site of original publication.
Creative Commons License
Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.
